Search academic texts

Information × Registration Number 0225U001204, (0124U000685) , R & D reports Title To optimize treatment tactics for patients with locally advanced and metastatic bladder cancer popup.stage_title На основі вивчення анатомо-функціональних змін в нирках та сечовивідних шляхах розробити тактику консервативного та комбінованого лікування хворих на місцево-поширений та метастатичний рак сечового міхура Head Stakhovskyi Eduard O., Доктор медичних наук Registration Date 27-01-2025 Organization National Cancer Institute popup.description1 To improve the quality of treatment of patients with locally advanced and metastatic bladder cancer by clarifying anatomical and functional changes in the kidneys and urinary tract, evaluating the effectiveness of chemotherapy, improving surgical tactics, and developing a new combined treatment algorithm based on them. popup.description2 Research Object: 483 patients diagnosed with locally advanced bladder cancer (T3b-T4) and metastatic bladder cancer (any T, N1-3, or M1). Objective: To enhance the quality of treatment for patients with locally advanced and metastatic bladder cancer by refining the understanding of anatomical and functional changes in the kidneys and urinary tract, improving indications for surgical intervention, and determining the effectiveness of surgical strategies in comprehensive treatment. Research Methods: Clinical, laboratory, genetic, radiological, and statistical methods. Results: The study established that the primary symptoms and syndromes of locally advanced and metastatic bladder cancer include hematuria (88.6%), dysuria (51.5%), and pain syndrome (32.3%). Locally advanced and metastatic bladder cancer is complicated by upper urinary tract dysfunction in 47.4% of cases, with bilateral ureterohydronephrosis occurring in 21.9% of cases. This condition leads to the development of chronic kidney disease (CKD) in 44.7% of cases, primarily due to late diagnosis, invasive tumor growth, high recurrence rates, patient age, and comorbid conditions. It has been demonstrated that the primary pathomorphological features contributing to the high aggressiveness of tumors, which lead to the development of locally advanced and metastatic bladder cancer, are the significant proportion of poorly and undifferentiated forms of transitional cell carcinoma (62.7%) and the high prevalence of squamous cell metaplasia (32.2%). Genetic analysis revealed that the A313G polymorphism of the GSTP1 gene correlates with the response to cisplatin treatment in patients with bladder cancer. This finding may serve as a predictor of the efficacy of cisplatin-based chemotherapy. Product Description popup.authors Vitruk Yurii V. Voilenko Oleh A. Hrechko Bohdan O. Kononenko Oleksii A. Koshel Denys O. Tymoshenko Andrii V. popup.nrat_date 2025-01-27 Close